<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04167098</url>
  </required_header>
  <id_info>
    <org_study_id>2845/2019</org_study_id>
    <nct_id>NCT04167098</nct_id>
  </id_info>
  <brief_title>Effectiveness of Platelet-rich Plasma for Treatment of Trigger Finger</brief_title>
  <official_title>A Prospective Randomized Placebo-controlled Trial Comparing Platelet-rich Plasma and Corticosteroid Injection for Treatment of Trigger Finger</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Töölö Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Töölö Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study purpose is to evaluate the effectiveness of Platelet-rich Plasma (PRP) injection in the
      treatment of trigger finger. We compare PRP to a corticosteroid (methylprednisolone)
      injection in a prospective randomized triple-blind placebo-controlled study.

      Patients with clinically confirmed trigger finger are randomized (1:1:1 computer generated
      sequence with random block size) to three parallel groups and will receive an injection of
      either PRP, corticosteroid or placebo (0.9% saline) around the affected tendon sheath in a
      double-blind setting.

      Baseline data is collected and is followed by a phone call at 1 month, and follow-up visits
      at 3, 6, 12 and 24 months after the intervention. Unveiling of the allocation is at 6 months
      post-intervention.

      The primary outcome measures are:

        -  Symptom resolution

        -  Patient-Rated Wrist Evaluation

      Secondary outcomes:

        -  Quick-Disabilities of the Arm, Shoulder and Hand

        -  Pain Visual Analogue Score

        -  Global improvement (7-step Likert-scale)

        -  Grip strength

        -  Finger range of motion
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2019</start_date>
  <completion_date type="Anticipated">July 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Symptom resolution</measure>
    <time_frame>24 months</time_frame>
    <description>4-step Likert (0 = no response; 1 = partial response, but not satisfactory, warranting further treatment; 2 = partial response, satisfactory, not warranting further treatment; 3 = complete resolution of symptoms and signs)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient-Rated Wrist Evaluation</measure>
    <time_frame>24 months</time_frame>
    <description>The PRWE comprises 15 questions to measure wrist pain and disability in daily activities. In PRWE patients rate wrist pain and disability from 0 to 10 and it consists two subscales: Pain and Function (0=best possible outcome, 10=worst possible outcome)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quick-Disabilities of the Arm, Shoulder and Hand</measure>
    <time_frame>24 months</time_frame>
    <description>he QuickDASH is self-reported questionnaire and shortened version of DASH outcome measure to measure physical function and symptoms in people with any or multiple musculoskeletal disorders of the upper limb in 11 dimensions in 1-5 scale (1=best possible outcome, 5=worst possible outcome)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain (Visual Analogue Scale)</measure>
    <time_frame>24 months</time_frame>
    <description>The VAS is derived by health care professional question of pain in scale 0 to 10 (0=no pain, 10=worst possible pain).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global improvement</measure>
    <time_frame>24 months</time_frame>
    <description>Global rating to treatment effect will be evaluated by question: &quot;How would you rate the function of your hand compared to the situation before the treatment?&quot;. The options are in 5-step Likert scale from (-2) Much worse to (+2) Much better</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Grip strength</measure>
    <time_frame>24 months</time_frame>
    <description>Grip strength is measured with a dynamometer in kg as the mean of three measurements. It will be numbered in kg and percentage of the unaffected side.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Finger range of motion (ROM)</measure>
    <time_frame>24 months</time_frame>
    <description>The ROM of the finger is measured on both hands with a handheld goniometer in degrees.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Tendon Entrapment</condition>
  <arm_group>
    <arm_group_label>Platelet-Rich Plasma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Corticosteroid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>0.9% saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>PRP injection</intervention_name>
    <description>0.5 ml Platelet-rich Plasma around A1 tendon sheath</description>
    <arm_group_label>Platelet-Rich Plasma</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Corticosteroid injection</intervention_name>
    <description>0.5 ml methylprednisolone around A1 tendon sheath</description>
    <arm_group_label>Corticosteroid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo injection</intervention_name>
    <description>0.5 ml 0.9% saline around A1 tendon sheath</description>
    <arm_group_label>0.9% saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 - 75

          -  Symptom duration &gt; 3 months

        Exclusion Criteria:

          -  Diabetes

          -  Rheumatoid arthritis or other condition requiring continuous oral corticosteroids

          -  Previous history of surgery or injection to the affected ray

          -  Alcohol or drug abuse

          -  Mental instability
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Samuli Aspinen, M.D., Ph.D</last_name>
    <phone>+358406360546</phone>
    <email>samuli.aspinen@hus.fi</email>
  </overall_contact>
  <location>
    <facility>
      <name>Töölö Hospital (Helsinki University Hospital)</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samuli Aspinen, M.D., Ph.D.</last_name>
      <phone>+358406360546</phone>
      <email>samuli.aspinen@hus.fi</email>
    </contact>
    <contact_backup>
      <last_name>Jussi Kosola, M.D., Ph.D.</last_name>
      <email>jussi.kosola@helsinki.fi</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>November 10, 2019</study_first_submitted>
  <study_first_submitted_qc>November 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 18, 2019</study_first_posted>
  <last_update_submitted>February 8, 2020</last_update_submitted>
  <last_update_submitted_qc>February 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Töölö Hospital</investigator_affiliation>
    <investigator_full_name>Samuli Aspinen</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <keyword>Platelet-Rich Plasma</keyword>
  <keyword>Trigger Finger</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trigger Finger Disorder</mesh_term>
    <mesh_term>Tendon Entrapment</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

